Show simple item record

dc.contributor.authorLeang, R
dc.contributor.authorKhu, NH
dc.contributor.authorMukaka, M
dc.contributor.authorDebackere, M
dc.contributor.authorTripura, R
dc.contributor.authorKheang, ST
dc.contributor.authorChy, S
dc.contributor.authorKak, N
dc.contributor.authorBuchy, P
dc.contributor.authorTarantola, A
dc.contributor.authorMenard, D
dc.contributor.authorRoca-Felterer, A
dc.contributor.authorFairhurst, RM
dc.contributor.authorKheng, S
dc.contributor.authorMuth, S
dc.contributor.authorNgak, S
dc.contributor.authorDondorp, AM
dc.contributor.authorWhite, NJ
dc.contributor.authorTaylor, WRJ
dc.date.accessioned2016-11-06T13:09:08Z
dc.date.available2016-11-06T13:09:08Z
dc.date.issued2016-10-27
dc.date.submitted2016-10-31
dc.identifier.citationAn Optimised Age-Based Dosing Regimen for Single Low-Dose Primaquine For Blocking Malaria Transmission in Cambodia. 2016, 14 (1):171 BMC Meden
dc.identifier.issn1741-7015
dc.identifier.pmid27784313
dc.identifier.doi10.1186/s12916-016-0701-8
dc.identifier.urihttp://hdl.handle.net/10144/618686
dc.description.abstractIn 2012, the World Health Organization recommended the addition of single low-dose primaquine (SLDPQ, 0.25 mg base/kg body weight) to artemisinin combination therapies to block the transmission of Plasmodium falciparum without testing for glucose-6-phosphate dehydrogenase deficiency. The targeted group was non-pregnant patients aged ≥ 1 year (later changed to ≥ 6 months) with acute uncomplicated falciparum malaria, primarily in countries with artemisinin-resistant P. falciparum (ARPf). No dosing regimen was suggested, leaving malaria control programmes and clinicians in limbo. Therefore, we designed a user-friendly, age-based SLDPQ regimen for Cambodia, the country most affected by ARPf.
dc.languageENG
dc.language.isoenen
dc.publisherBioMed Centralen
dc.rightsArchived with thanks to BMC Medicineen
dc.titleAn Optimised Age-Based Dosing Regimen for Single Low-Dose Primaquine For Blocking Malaria Transmission in Cambodiaen
dc.identifier.journalBMC Medicineen
refterms.dateFOA2019-03-04T12:56:20Z
html.description.abstractIn 2012, the World Health Organization recommended the addition of single low-dose primaquine (SLDPQ, 0.25 mg base/kg body weight) to artemisinin combination therapies to block the transmission of Plasmodium falciparum without testing for glucose-6-phosphate dehydrogenase deficiency. The targeted group was non-pregnant patients aged ≥ 1 year (later changed to ≥ 6 months) with acute uncomplicated falciparum malaria, primarily in countries with artemisinin-resistant P. falciparum (ARPf). No dosing regimen was suggested, leaving malaria control programmes and clinicians in limbo. Therefore, we designed a user-friendly, age-based SLDPQ regimen for Cambodia, the country most affected by ARPf.


Files in this item

Thumbnail
Name:
Leang R et al - 2016 - An optimized ...
Size:
975.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record